{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T06:55:34Z","timestamp":1791096934794,"version":"4.1.0"},"reference-count":97,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","license":[{"start":{"date-parts":[[2011,4,1]],"date-time":"2011-04-01T00:00:00Z","timestamp":1301616000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,4]]},"DOI":"10.1038\/ajg.2011.103","type":"journal-article","created":{"date-parts":[[2011,3,22]],"date-time":"2011-03-22T11:39:16Z","timestamp":1300793956000},"page":"685-698","source":"Crossref","is-referenced-by-count":288,"title":["Assessing Response and Loss of Response to Biological Therapies in IBD"],"prefix":"10.14309","volume":"106","author":[{"given":"Henit","family":"Yanai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen B","family":"Hanauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-16-20210306","doi-asserted-by":"crossref","first-page":"895","DOI":"10.7326\/0003-4819-143-12-200512200-00007","article-title":"New concepts in the pathophysiology of inflammatory bowel disease.","volume":"143","author":"Bamias","year":"2005","journal-title":"Ann Intern Med"},{"key":"R2-16-20210306","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1016\/S0140-6736(07)60750-8","article-title":"Inflammatory bowel disease: cause and immunobiology.","volume":"369","author":"Baumgart","year":"2007","journal-title":"Lancet"},{"key":"R3-16-20210306","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1053\/j.gastro.2007.08.032","article-title":"The genetics of inflammatory bowel disease.","volume":"133","author":"Cho","year":"2007","journal-title":"Gastroenterology"},{"key":"R4-16-20210306","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1038\/nature06005","article-title":"Unravelling the pathogenesis of inflammatory bowel disease.","volume":"448","author":"Xavier","year":"2007","journal-title":"Nature"},{"key":"R5-16-20210306","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.clim.2007.08.013","article-title":"TNFalpha blockade in human diseases: mechanisms and future directions.","volume":"126","author":"Wong","year":"2008","journal-title":"Clin Immunol"},{"key":"R6-16-20210306","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/0140-6736(92)90999-J","article-title":"Tumour necrosis factor alpha in stool as a marker of intestinal inflammation.","volume":"339","author":"Braegger","year":"1992","journal-title":"Lancet"},{"key":"R7-16-20210306","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1111\/j.1365-2249.1990.tb03334.x","article-title":"Tumour necrosis factor-alpha and interferon-gamma production measured at the single cell level in normal and inflamed human intestine.","volume":"81","author":"MacDonald","year":"1990","journal-title":"Clin Exp Immunol"},{"key":"R8-16-20210306","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S0140-6736(98)03339-X","article-title":"Tumour necrosis factor alpha and interleukin 1beta in relapse of Crohns disease.","volume":"353","author":"Schreiber","year":"1999","journal-title":"Lancet"},{"key":"R9-16-20210306","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/S0140-6736(02)08512-4","article-title":"Maintenance infliximab for Crohns disease: the ACCENT I randomised trial.","volume":"359","author":"Hanauer","year":"2002","journal-title":"Lancet"},{"key":"R10-16-20210306","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1056\/NEJMoa030815","article-title":"Infliximab maintenance therapy for fistulizing Crohns disease.","volume":"350","author":"Sands","year":"2004","journal-title":"N Engl J Med"},{"key":"R11-16-20210306","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1056\/NEJM199710093371502","article-title":"A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohns disease. Crohns Disease cA2 Study Group.","volume":"337","author":"Targan","year":"1997","journal-title":"N Engl J Med"},{"key":"R12-16-20210306","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1053\/j.gastro.2007.05.006","article-title":"American gastroenterological association consensus development conference on the use of biologics in the treatment of inflammatory bowel disease, June 21-23, 2006.","volume":"133","author":"Clark","year":"2007","journal-title":"Gastroenterology"},{"key":"R13-16-20210306","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1097\/00054725-200207000-00001","article-title":"Infliximab improves quality of life in patients with Crohns disease.","volume":"8","author":"Lichtenstein","year":"2002","journal-title":"Inflamm Bowel Dis"},{"key":"R14-16-20210306","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1053\/j.gastro.2006.11.041","article-title":"Adalimumab for maintenance of clinical response and remission in patients with Crohns disease: the CHARM trial.","volume":"132","author":"Colombel","year":"2007","journal-title":"Gastroenterology"},{"key":"R15-16-20210306","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1136\/gut.2008.159251","article-title":"Adalimumab for the treatment of fistulas in patients with Crohns disease.","volume":"58","author":"Colombel","year":"2009","journal-title":"Gut"},{"key":"R17-16-20210306","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.cgh.2010.01.014","article-title":"Continuous therapy with certolizumab pegol maintains remission of patients with Crohns disease for up to 18 months.","volume":"8","author":"Lichtenstein","year":"2010","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R18-16-20210306","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1056\/NEJMoa067594","article-title":"Certolizumab pegol for the treatment of Crohns disease.","volume":"357","author":"Sandborn","year":"2007","journal-title":"N Engl J Med"},{"key":"R19-16-20210306","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1136\/gut.2006.106781","article-title":"Adalimumab for maintenance treatment of Crohns disease: results of the CLASSIC II trial.","volume":"56","author":"Sandborn","year":"2007","journal-title":"Gut"},{"key":"R20-16-20210306","doi-asserted-by":"crossref","first-page":"829","DOI":"10.7326\/0003-4819-146-12-200706190-00159","article-title":"Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial.","volume":"146","author":"Sandborn","year":"2007","journal-title":"Ann Intern Med"},{"key":"R21-16-20210306","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1056\/NEJMoa062897","article-title":"Maintenance therapy with certolizumab pegol for Crohns disease.","volume":"357","author":"Schreiber","year":"2007","journal-title":"N Engl J Med"},{"key":"R22-16-20210306","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1053\/j.gastro.2005.06.064","article-title":"A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohns disease.","volume":"129","author":"Schreiber","year":"2005","journal-title":"Gastroenterology"},{"key":"R23-16-20210306","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1053\/gast.2001.28674","article-title":"Etanercept for active Crohns disease: a randomized, double-blind, placebo-controlled trial.","volume":"121","author":"Sandborn","year":"2001","journal-title":"Gastroenterology"},{"key":"R24-16-20210306","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1097\/BOR.0b013e328329ed8b","article-title":"Dealing with immunogenicity of biologicals: assessment and clinical relevance.","volume":"21","author":"Wolbink","year":"2009","journal-title":"Curr Opin Rheumatol"},{"key":"R25-16-20210306","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1016\/j.cgh.2006.06.025","article-title":"Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohns disease.","volume":"4","author":"Maser","year":"2006","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R26-16-20210306","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1056\/NEJMoa020888","article-title":"Influence of immunogenicity on the long-term efficacy of infliximab in Crohns disease.","volume":"348","author":"Baert","year":"2003","journal-title":"N Engl J Med"},{"key":"R27-16-20210306","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1111\/j.1365-2036.2008.03828.x","article-title":"Immunogenicity negatively influences the outcome of adalimumab treatment in Crohns disease.","volume":"28","author":"West","year":"2008","journal-title":"Aliment Pharmacol Ther"},{"key":"R28-16-20210306","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1136\/gut.2008.163642","article-title":"Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study.","volume":"58","author":"Fidder","year":"2009","journal-title":"Gut"},{"key":"R29-16-20210306","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.cgh.2006.03.002","article-title":"Serious infections and mortality in association with therapies for Crohns disease: TREAT registry.","volume":"4","author":"Lichtenstein","year":"2006","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R30-16-20210306","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1053\/j.gastro.2008.01.012","article-title":"Risk factors for opportunistic infections in patients with inflammatory bowel disease.","volume":"134","author":"Toruner","year":"2008","journal-title":"Gastroenterology"},{"key":"R31-16-20210306","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1016\/j.cgh.2009.01.004","article-title":"Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohns disease: a meta-analysis.","volume":"7","author":"Siegel","year":"2009","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R32-16-20210306","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1097\/MPG.0b013e31802f6424","article-title":"Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease.","volume":"44","author":"Mackey","year":"2007","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"R33-16-20210306","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1136\/gut.2008.163279","article-title":"Hepatosplenic T cell lymphoma in inflammatory bowel disease.","volume":"57","author":"Shale","year":"2008","journal-title":"Gut"},{"key":"R34-16-20210306","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1056\/NEJMoa050516","article-title":"Infliximab for induction and maintenance therapy for ulcerative colitis.","volume":"353","author":"Rutgeerts","year":"2005","journal-title":"N Engl J Med"},{"key":"R35-16-20210306","first-page":"995","article-title":"Therapeutic value of alpha-4 integrin blockade in inflammatory bowel disease: the role of natalizumab.","volume":"3","author":"Ghosh","year":"2003","journal-title":"Expert Opin Biol Ther"},{"key":"R36-16-20210306","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1056\/NEJMoa020732","article-title":"Natalizumab for active Crohns disease.","volume":"348","author":"Ghosh","year":"2003","journal-title":"N Engl J Med"},{"key":"R37-16-20210306","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1056\/NEJMoa054693","article-title":"Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy.","volume":"354","author":"Yousry","year":"2006","journal-title":"N Engl J Med"},{"key":"R38-16-20210306","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1365-2036.2006.03134.x","article-title":"Review article: altering the natural history of Crohns diseaseevidence for and against current therapies.","volume":"25","author":"Vermeire","year":"2007","journal-title":"Aliment Pharmacol Ther"},{"key":"R39-16-20210306","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1002\/ibd.21034","article-title":"Endpoints for clinical trials evaluating disease modification and structural damage in adults with Crohns disease.","volume":"15","author":"DHaens","year":"2009","journal-title":"Inflamm Bowel Dis"},{"key":"R40-16-20210306","doi-asserted-by":"crossref","first-page":"3782","DOI":"10.1002\/art.22214","article-title":"Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor infliximab.","volume":"54","author":"Bendtzen","year":"2006","journal-title":"Arthritis Rheum"},{"key":"R41-16-20210306","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1111\/j.1572-0241.2007.01638.x","article-title":"Tumor necrosis factor-alpha binding capacity and anti-infliximab antibodies measured by fluid-phase radioimmunoassays as predictors of clinical efficacy of infliximab in Crohns disease.","volume":"103","author":"Ainsworth","year":"2008","journal-title":"Am J Gastroenterol"},{"key":"R42-16-20210306","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1111\/j.1365-2249.2008.03773.x","article-title":"Non-response to infliximab may be due to innate neutralizing anti-tumour necrosis factor-alpha antibodies.","volume":"154","author":"Ebert","year":"2008","journal-title":"Clin Exp Immunol"},{"key":"R43-16-20210306","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1097\/00054725-200207000-00002","article-title":"Long-term evolution of disease behavior of Crohns disease.","volume":"8","author":"Cosnes","year":"2002","journal-title":"Inflamm Bowel Dis"},{"key":"R44-16-20210306","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1046\/j.1365-2036.2003.01672.x","article-title":"Response to infliximab is related to disease duration in paediatric Crohns disease.","volume":"18","author":"Lionetti","year":"2003","journal-title":"Aliment Pharmacol Ther"},{"key":"R45-16-20210306","doi-asserted-by":"crossref","first-page":"3189","DOI":"10.1111\/j.1572-0241.2000.03263.x","article-title":"Prolonged duration of response to infliximab in early but not late pediatric Crohns disease.","volume":"95","author":"Kugathasan","year":"2000","journal-title":"Am J Gastroenterol"},{"key":"R47-16-20210306","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1097\/01.fpc.0000230421.12844.fd","article-title":"Polymorphism in IgG Fc receptor gene FCGR3A and response to infliximab in Crohns disease: a subanalysis of the ACCENT I study.","volume":"16","author":"Louis","year":"2006","journal-title":"Pharmacogenet Genomics"},{"key":"R48-16-20210306","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1111\/j.1365-2036.2004.01871.x","article-title":"Association between polymorphism in IgG Fc receptor IIIa coding gene and biological response to infliximab in Crohns disease.","volume":"19","author":"Louis","year":"2004","journal-title":"Aliment Pharmacol Ther"},{"key":"R49-16-20210306","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1136\/gut.2009.178665","article-title":"Mucosal gene signatures to predict response to infliximab in patients with ulcerative colitis.","volume":"58","author":"Arijs","year":"2009","journal-title":"Gut"},{"key":"R50-16-20210306","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1111\/j.1365-2036.2005.02635.x","article-title":"Polymorphisms in apoptosis genes predict response to infliximab therapy in luminal and fistulizing Crohns disease.","volume":"22","author":"Hlavaty","year":"2005","journal-title":"Aliment Pharmacol Ther"},{"key":"R51-16-20210306","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1136\/ard.2006.065615","article-title":"Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis.","volume":"66","author":"Bartelds","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"R52-16-20210306","doi-asserted-by":"crossref","first-page":"2645","DOI":"10.1002\/jps.20178","article-title":"Antibody pharmacokinetics and pharmacodynamics.","volume":"93","author":"Lobo","year":"2004","journal-title":"J Pharm Sci"},{"key":"R53-16-20210306","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1053\/gast.2003.50145","article-title":"Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohns disease: a randomized controlled trial.","volume":"124","author":"Farrell","year":"2003","journal-title":"Gastroenterology"},{"key":"R54-16-20210306","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1136\/gut.2006.099978","article-title":"Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohns disease.","volume":"56","author":"Vermeire","year":"2007","journal-title":"Gut"},{"key":"R55-16-20210306","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/S1542-3565(04)00238-1","article-title":"Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohns disease.","volume":"2","author":"Hanauer","year":"2004","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R56-16-20210306","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/00365520802699278","article-title":"Individual medicine in inflammatory bowel disease: monitoring bioavailability, pharmacokinetics and immunogenicity of anti-tumour necrosis factor-alpha antibodies.","volume":"44","author":"Bendtzen","year":"2009","journal-title":"Scand J Gastroenterol"},{"key":"R57-16-20210306","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1093\/rheumatology\/kem261","article-title":"Monitoring patients treated with anti-TNF-alpha biopharmaceuticals: assessing serum infliximab and anti-infliximab antibodies.","volume":"46","author":"Svenson","year":"2007","journal-title":"Rheumatology (Oxford)"},{"key":"R58-16-20210306","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1016\/0161-5890(93)90106-L","article-title":"Construction and initial characterization of a mouse-human chimeric anti-TNF antibody.","volume":"30","author":"Knight","year":"1993","journal-title":"Mol Immunol"},{"key":"R59-16-20210306","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1002\/art.10302","article-title":"The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trial.","volume":"46","author":"St Clair","year":"2002","journal-title":"Arthritis Rheum"},{"key":"R60-16-20210306","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1097\/FTD.0b013e3181cc6fef","article-title":"Trough infliximab concentrations predict efficacy and sustained control of disease activity in rheumatoid arthritis.","volume":"32","author":"Mulleman","year":"2010","journal-title":"Ther Drug Monit"},{"key":"R61-16-20210306","doi-asserted-by":"crossref","first-page":"83","DOI":"10.3109\/s10165-006-0544-9","article-title":"A relationship between pharmacokinetics (PK) and the efficacy of infliximab for patients with rheumatoid arthritis: characterization of infliximab-resistant cases and PK-based modified therapy.","volume":"17","author":"Mori","year":"2007","journal-title":"Mod Rheumatol"},{"key":"R62-16-20210306","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1136\/ard.2004.030452","article-title":"Relationship between serum trough infliximab levels, pretreatment C reactive protein levels, and clinical response to infliximab treatment in patients with rheumatoid arthritis.","volume":"64","author":"Wolbink","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"R63-16-20210306","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1136\/gut.2009.183095","article-title":"Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis.","volume":"59","author":"Seow","year":"2010","journal-title":"Gut"},{"key":"R64-16-20210306","first-page":"741","article-title":"Evaluation of potential correlations between serum adalimumab concentration and remission in patients with Crohns disease in classic I and II.","volume":"138","author":"Li","year":"2010","journal-title":"Gastroenterology"},{"key":"R65-16-20210306","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1053\/j.gastro.2009.07.062","article-title":"Influence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohns disease.","volume":"137","author":"Karmiris","year":"2009","journal-title":"Gastroenterology"},{"key":"R66-16-20210306","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1136\/ard.2008.092833","article-title":"Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis.","volume":"68","author":"Radstake","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"R67-16-20210306","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1053\/j.gastro.2003.11.014","article-title":"Comparison of scheduled and episodic treatment strategies of infliximab in Crohns disease.","volume":"126","author":"Rutgeerts","year":"2004","journal-title":"Gastroenterology"},{"key":"R68-16-20210306","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1136\/gut.2008.155812","article-title":"Long-term outcome of treatment with infliximab in 614 patients with Crohns disease: results from a single-centre cohort.","volume":"58","author":"Schnitzler","year":"2009","journal-title":"Gut"},{"key":"R69-16-20210306","first-page":"2563","article-title":"Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis).","volume":"30","author":"Furst","year":"2003","journal-title":"J Rheumatol"},{"key":"R70-16-20210306","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1002\/art.20217","article-title":"Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial.","volume":"50","author":"Keystone","year":"2004","journal-title":"Arthritis Rheum"},{"key":"R71-16-20210306","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1056\/NEJM200011303432202","article-title":"Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group.","volume":"343","author":"Lipsky","year":"2000","journal-title":"N Engl J Med"},{"key":"R72-16-20210306","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1016\/S0140-6736(99)05246-0","article-title":"Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group.","volume":"354","author":"Maini","year":"1999","journal-title":"Lancet"},{"key":"R73-16-20210306","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1002\/art.10697","article-title":"Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial.","volume":"48","author":"Weinblatt","year":"2003","journal-title":"Arthritis Rheum"},{"key":"R74-16-20210306","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1016\/S0149-2918(03)80164-9","article-title":"Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study.","volume":"25","author":"Weisman","year":"2003","journal-title":"Clin Ther"},{"key":"R75-16-20210306","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1056\/NEJMoa043335","article-title":"Natalizumab induction and maintenance therapy for Crohns disease.","volume":"353","author":"Sandborn","year":"2005","journal-title":"N Engl J Med"},{"key":"R76-16-20210306","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1053\/j.gastro.2008.03.004","article-title":"Withdrawal of immunosuppression in Crohns disease treated with scheduled infliximab maintenance: a randomized trial.","volume":"134","author":"Van Assche","year":"2008","journal-title":"Gastroenterology"},{"key":"R77-16-20210306","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/S0016-5085(09)60521-7","article-title":"751f one year data from the sonic study: a randomized, double-blind trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with Crohns disease naive to immunomodulators and biologic therapy.","volume":"136","author":"Sandborn","year":"2009","journal-title":"Gastroenterology"},{"key":"R78-16-20210306","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1007\/s10067-008-0866-4","article-title":"An open-label pilot study of the effectiveness of adalimumab in patients with rheumatoid arthritis and previous infliximab treatment: relationship to reasons for failure and anti-infliximab antibody status.","volume":"27","author":"van der Bijl","year":"2008","journal-title":"Clin Rheumatol"},{"key":"R79-16-20210306","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1111\/j.1365-2036.2007.03253.x","article-title":"Adalimumab in patients with Crohns diseasesafety and efficacy in an open-label single centre study.","volume":"25","author":"Seiderer","year":"2007","journal-title":"Aliment Pharmacol Ther"},{"key":"R80-16-20210306","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1111\/j.1365-2036.2007.03583.x","article-title":"The use of adalimumab in the management of refractory Crohns disease.","volume":"27","author":"Ho","year":"2008","journal-title":"Aliment Pharmacol Ther"},{"key":"R81-16-20210306","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1002\/ibd.20426","article-title":"Successful induction of clinical response and remission with certolizumab pegol in Crohns disease patients refractory or intolerant to infliximab: a real-life multicenter experience of compassionate use.","volume":"14","author":"Danese","year":"2008","journal-title":"Inflamm Bowel Dis"},{"issue":"Suppl 1","key":"R82-16-20210306","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1186\/ar2666","article-title":"Treatment options in patients with rheumatoid arthritis failing initial TNF inhibitor therapy: a critical review.","volume":"11","author":"Rubbert-Roth","year":"2009","journal-title":"Arthritis Res Ther"},{"key":"R83-16-20210306","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1053\/j.gastro.2007.03.024","article-title":"Natalizumab for the treatment of active Crohns disease: results of the ENCORE Trial.","volume":"132","author":"Targan","year":"2007","journal-title":"Gastroenterology"},{"key":"R84-16-20210306","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1038\/ajg.2010.9","article-title":"Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease.","volume":"105","author":"Afif","year":"2010","journal-title":"Am J Gastroenterol"},{"key":"R85-16-20210306","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1111\/j.1365-2036.2007.03548.x","article-title":"Infliximab dose escalation vs. initiation of adalimumab for loss of response in Crohns disease: a cost-effectiveness analysis.","volume":"26","author":"Kaplan","year":"2007","journal-title":"Aliment Pharmacol Ther"},{"key":"R86-16-20210306","first-page":"A505","article-title":"Re-induction and maintenance therapy with subcutaneous certolizumab pegol in patients with Crohns disease following treatment failure: PRECiSE 4 results.","volume":"132","author":"Sandborn","year":"2007","journal-title":"Gastroenterology"},{"key":"R87-16-20210306","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1111\/j.1365-2036.2009.03955.x","article-title":"Review article: anti TNF-alpha induced psoriasis in patients with inflammatory bowel disease.","volume":"29","author":"Fiorino","year":"2009","journal-title":"Aliment Pharmacol Ther"},{"key":"R88-16-20210306","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.semarthrit.2008.06.004","article-title":"Emergence of Crohns disease during treatment with the anti-tumor necrosis factor agent etanercept for ankylosing spondylitis: possible mechanisms of action.","volume":"39","author":"Haraoui","year":"2009","journal-title":"Semin Arthritis Rheum"},{"key":"R89-16-20210306","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1002\/art.22025","article-title":"Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks.","volume":"54","author":"Cohen","year":"2006","journal-title":"Arthritis Rheum"},{"key":"R90-16-20210306","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1056\/NEJMoa050524","article-title":"Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition.","volume":"353","author":"Genovese","year":"2005","journal-title":"N Engl J Med"},{"key":"R91-16-20210306","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1002\/art.22520","article-title":"B cell depletion may be more effective than switching to an alternative anti-tumor necrosis factor agent in rheumatoid arthritis patients with inadequate response to anti-tumor necrosis factor agents.","volume":"56","author":"Finckh","year":"2007","journal-title":"Arthritis Rheum"},{"key":"R92-16-20210306","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1136\/ard.2008.105064","article-title":"Which subgroup of rheumatoid arthritis patients benefits from switching to rituximab versus alternative anti-TNF agents after previous failure to anti-TNF agent?","volume":"69","author":"Finckh","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"R93-16-20210306","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1111\/j.1572-0241.2004.40462.x","article-title":"An open-label study of the human anti-TNF monoclonal antibody adalimumab in subjects with prior loss of response or intolerance to infliximab for Crohns disease.","volume":"99","author":"Sandborn","year":"2004","journal-title":"Am J Gastroenterol"},{"key":"R94-16-20210306","doi-asserted-by":"crossref","first-page":"67-68","DOI":"10.1016\/S0016-5085(08)60318-2","article-title":"Efficacy and safety of certolizumab pegol in patients with active Crohns disease who previously lost response or were intolerant to infliximab: open-label induction preliminary results of the WELCOME study.","volume":"134","author":"Vermeire","year":"2008","journal-title":"Gastroenterology"},{"key":"R95-16-20210306","first-page":"133-134","article-title":"920 Adalimumab maintains long-term remission in moderately to severely active Crohns disease after infliximab failure: 1-year follow-up of gain trial.","volume":"134","author":"Panaccione","year":"2008","journal-title":"Gastroenterology"},{"key":"R96-16-20210306","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1111\/j.1365-2036.2008.03902.x","article-title":"Adalimumab for Crohns disease with intolerance or lost response to infliximab: a 3-year single-centre experience.","volume":"29","author":"Oussalah","year":"2009","journal-title":"Aliment Pharmacol Ther"},{"key":"R97-16-20210306","first-page":"474-475","article-title":"T1061 Improvement in short inflammatory bowel disease questionnaire scores in adalimumab-treated Crohns disease patients who failed infliximab (CHOICE trial).","volume":"134","author":"Lichtiger","year":"2008","journal-title":"Gastroenterology"},{"key":"R98-16-20210306","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1111\/j.1365-2036.2009.04130.x","article-title":"The efficacy and safety of a third anti-TNF monoclonal antibody in Crohns disease after failure of two other anti-TNF antibodies.","volume":"31","author":"Allez","year":"2010","journal-title":"Aliment Pharmacol Ther"},{"key":"R101-16-20210306","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.3109\/00365521.2010.510572","article-title":"Long-term effects and colectomy rates in ulcerative colitis patients treated with infliximab: a Danish single center experience.","volume":"45","author":"Teisner","year":"2010","journal-title":"Scand J Gastroenterol"}],"container-title":["American Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/ajg2011103.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/ajg2011103","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/ajg2011103.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/www.ovid.com\/00000434-201104000-00016","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T13:35:48Z","timestamp":1786541748000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00000434-201104000-00016"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,4]]},"references-count":97,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2011]]}},"URL":"https:\/\/doi.org\/10.1038\/ajg.2011.103","relation":{},"ISSN":["0002-9270"],"issn-type":[{"value":"0002-9270","type":"print"}],"subject":[],"published":{"date-parts":[[2011,4]]}}}